anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Current literature provides insufficient information on the degree of cognitive impairment during and after electroconvulsive therapy (ECT), mostly due to the fact that applied tests lacked sensitivity and flexibility. Our goal was to evaluate cognitive functioning in adult depressed patients treated with bi \& uni lateral \& ECT, using tests sensitive for detection of possible acute and medium-term memory changes.(9) Major depressive disorder (MDD) is estimated to affect around 16 million Americans (Substance Abuse and Mental Health Services Administration \[SAMHSA\], 2013) and, according to the World Health Organization, is the leading cause of disability worldwide (World Health Organization 2012). Among In the U.S. workforce, the prevalence of MDD has been estimated at 7.6% .(2) Electroconvulsive therapy (ECT) is an effective treatment for severe depression but entails cognitive adverse effects, particularly the effects on memory. ECT may cause a temporary deficit in the cognitive processes of information encoding, consolidation, and retrieval. Transient memory disturbances are regarded as an inevitable adverse effect of therapeutic convulsions. Various strategies have been tried to decrease the cognitive adverse effects while retaining the antidepressant effect, including the use of unilateral instead of bilateral electrode placement, changes in waveform, and reducing the electrical stimulus intensity, (4).
Using genes which have been experimentally-validated for diseases (functions) can develop machine learning methods to predict new disease/function-genes. However, the prediction of both function-genes and disease-genes faces the same problem: there are only certain positive examples, but no negative examples. To solve this problem, we proposed a function/disease-genes prediction algorithm based on network embedding (Variational Graph Auto-Encoders, VGAE) and one-class classification (Fast Minimum Covariance Determinant, Fast-MCD): VGAEMCD. Firstly, we constructed a protein-protein interaction (PPI) network centered on experimentally-validated genes; then VGAE was used to get the embeddings of nodes (genes) in the network; finally, the embeddings were input into the improved deep learning one-class classifier based on Fast-MCD to predict function/disease-genes. VGAEMCD can predict function-gene and disease-gene in a unified way, and only the experimentally-verified genes are needed to provide (no need for expression profile). VGAEMCD outperforms classical one-class classification algorithms in Recall, Precision, F-measure, Specificity, and Accuracy. Further experiments show that seven metrics of VGAEMCD are higher than those of state-of-art function/disease-genes prediction algorithms. The above results indicate that VGAEMCD can well learn the distribution characteristics of positive examples and accurately identify function/disease-genes.
The present invention provides a recombined herpes simplex virus whose natural packaging signal (pac) is deficient, a reformed packaging signal replaces the natural packaging signal (pac), wherein both ends of the packaging signal respectively have a recombined sequence (a loxP sequence), and the other point in a recombined virus genome is inserted with a code specially identifying a gene of the recombinase Cre of the recombined sequence. The Cre gene has an adjustable promoter (a metallothionein promoter) to control Cre expression. After the recombined virus infects a cell, a proper quantity of zinc ions are added to activate the metallothionein promoter, the recombinase Cre is expressed, recombination is generated between two loxP sequences mediated by the Cre, and the packaging signal is cut. Thereby, although the virus genome can copy and express various proteins, the virus genome can not be packed into a virus capsid, and therefore, a progeny virus is not generated. If the cell is not added with the zinc ions, the Cre is not expressed, the packaging signal on the recombined virus genome is not cut, and therefore, the recombined virus can be normally copied and carries out passage in the cell. The recombined virus provided by the present invention can be used as a helper virus of an amplicon carrier of the herpes simplex virus and is directly used as a gene treating carrier to be used for the treatment of malignant tumors and the preparation of vacant shells of the virus.
Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
PCT No. PCT/EP97/02244 Sec. 371 Date Oct. 6, 1998 Sec. 102(e) Date Oct. 6, 1998 PCT Filed May 2, 1997 PCT Pub. No. WO97/43290 PCT Pub. Date Nov. 20, 1997The present invention relates to camptothecin-skeleton alkaloids isolated from Mappia foetida or obtained by semi-synthesis from said alkaloids. Mappia foetida, a plant growing in the Indian subcontinent, is known to contain in its various parts, mainly in the seeds, camptothecin, mappicine and foetidine I and II (EP-A-685481). The alkaloids of the invention have the following general formula: in which R is a hydrogen atom or a methoxy group; R1 is hydroxy, an OM group wherein M is an alkali cation, preferably sodium or potassium, a C1-C6 alkoxy group, an optionally substituted phenoxy group, an amino, C1-C6 monoalkylamino or C2-C12 dialkylamino group in which the alkyl moiety is optionally substituted by amino groups, an arylamino group; R2 is a C1-C6 alkyl group or a group of formula COR3 wherein R3 is alkyl C1-C6 or optionally substituted phenyl or benzyl.
Participants will be offered a virtual reality (VR) device for up to 30 minutes for two separate sessions on postoperative day 1. The device will be pre-loaded with a variety of vetted and screened age-appropriate games.
PSLT will be performed using the Pascal Streamline 577 laser (Topcon Inc., Tokyo, Japan). The laser spot is directed at the anterior chamber angle encompassing the pigmented and non-pigmented trabecular meshwork. Laser power is titrated by placing a laser mark in the lower quadrant with an exposure duration of 10 milliseconds (ms). The initial energy of 500 megawatts (mW) is selected and the power is reduced or increased until a slight whitening of the trabecular meshwork is minimally noticed. This power is then maintained and the pulse duration is automatically reduced to 5ms to produce invisible injury. The treatment is administered in 32 steps, each pattern consists of 36 stitches: 3 rows of 13 stitches each (total of 1152), with zero space between adjacent stitches.
PURPOSE: A pharmaceutical composition containing Cornus kousa Burg. fruit extract is provided to suppress human acyl-CoA(hACAT) and to prevent and treat cardiovascular diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating cardiovascular diseases due to hypercholesterolemia contains Cornus kousa Burg. fruit extract as an active ingredient. The Cornus kousa Burg. fruit extract is isolated from Cornus kousa Burg. fruit using alcohol aqueous solution or isolated by double-boiling. The pharmaceutical composition contains Cornus kousa Burg. fruit fraction as an active ingredient. The fraction is obtained using ethyl acetate and H_2O and by extracting H_2O layer using n-butanol. The pharmaceutical composition also contains triterpene compounds from the fraction or pharmaceutically acceptable salt thereof as an active ingredient. The triterpene compounds is ursolic acid of chemical formula 1, corosolic acid of chemical formula 2, taraxasterol of chemical formula 3, betulinic acid of chemical formula 4, or betulinic aldehyde of chemical formula 5.
Patients receive oral ABT-888 twice daily on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21\* days in the absence of disease progression or unacceptable toxicity.
INTRODUCTION: Chronic Traumatic Encephalopathy (CTE) is a neurodegenerative disorder associated with repetitive head trauma. Historically, the diagnosis has been primarily clinical, which has hindered definitive early diagnosis and proactive intervention.
AREAS COVERED: The authors analyze the recent advancements in early diagnosis of CTE by examining biomarkers, imaging, and clinical decision tools. They discuss the identification of neuropathologies - such as tau aggregates - through novel techniques ranging from blood sampling and to brain density scanning. The reader will walk away with a better understanding of current advancements in early detection and be better equipped to deal with encephalopathies secondary to trauma in clinical practice.
EXPERT OPINION: Tremendous progress has been made in understanding the pathophysiology of CTE. Despite these advancements, CTE treatment is still primarily symptomatic rather than underlying disease. Future research should focus on integrating current understanding of CTE pathophysiology with treatment modalities.
A medical data processing system may associate a utilization score of a dataset with data in the dataset. For example, the medical data processing system may obtain a dataset including medical data. The medical data processing system may obtain an indication of a control program, and determine, for the control program, a utilization score of the dataset. The medical data processing system may associate the utilization score with the medical data in the dataset. The utilization score may indicate a level of valuableness of the dataset to the control program. For example, the medical data processing system may determine metadata associated with the dataset, retrieve the metadata associated with the dataset from a metadata repository, and determine the utilization score of the dataset based on the metadata associated with the dataset.
FIELD: medicine, oncology. SUBSTANCE: method involves administration to patients from the risk group of development of stomach cancer the preparation "Feokarpin" by oral route in the dose for 2 tablets, 3 times per a day, 30 min before eating, for 6 months. Method improves clinical and endoscopic pictures of precancer state, regression of precancer alternations in stomach mucosa, inhibits formation of carcinogenic nitroso- compound in stomach juice. Invention can be used for prophylaxis of stomach malignant tumors development. EFFECT: enhanced effectiveness of method, valuable anticancer properties of preparation. 1 tbl
PURPOSE: Assess the utility of a hands-on cadaver workshop for teaching abdominal wall reconstruction (AWR) using components separation technique.
METHODS: Over a year, from June 2022 to July 2023, 112 surgeons participated in seven training courses focused on the eTEP technique for inguinal and ventral hernias. The workshops covered theoretical learning sessions followed by hands-on training using frozen human cadavers. An online survey was used to know the influence of our workshop on the clinical practice of the attendees.
RESULTS: Out of 112 total participants, 70% (78) participants completed the survey. Among them, 58% (45) surgeons had over 10 years of experience. The workshop resulted in approximately 85% (66) of participants successfully adapting to eTEP. Confidence levels significantly increased for all steps of the technique after the workshop (p < 0.001, Rank-Biserial Correlation = -1.000). Participants expressed high satisfaction with the course.
CONCLUSION: The cadaver model training program was found to be effective in reducing the learning curve and being replicable. This suggests its potential for widespread implementation as an introductory training model for learning the anatomy of abdominal wall and adapting this for treating hernias requiring AWR.
PPC-5650 is a "asic-sensing ion channel"-1a antagonist that can block the acid-sensing ion channels, leading to a reduction in the pain signal under up-regulated conditions. A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered through an esophageal probe to assess local effects. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with PPC-5650 in one out of three visit days.
PCT No. PCT/JP91/01573 Sec. 371 Date May 18, 1993 Sec. 102(e) Date May 18, 1993 PCT Filed Nov. 18, 1991 PCT Pub. No. WO92/08975 PCT Pub. Date May 29, 1992.A test agent composition for dentistry comprises from 5 to 45% by weight of Hydrogenated Maltose Syrup, from 5 to 30% by weight of sorbitol, from 10 to 40% by weight of paratinose, from 5 to 20% by weight of water, from 5 to 37% by weight of a component selected from the group consisting of gelatin, starch and pectin, and from 0.1 to 10% by weight of a detection reagent selected from the group consisting of glucose, vitamins, amino acids, dyes, inorganic salts and other physiologically nontoxic substances, based on the total weight of the composition. The masticatory efficiency of a subject can be evaluated by having the subject chew the test agent composition for dentistry and determining the amount of the detection reagent transferred into the saliva of the subject.
Background & Objective: Assessment of muscularis propria invasion is a crucial step in the management of urothelial carcinoma since it necessitates aggressive treatment. The diagnosis of muscle invasion is a challenging process for pathologists. Artificial intelligence is developing rapidly and being implemented in various fields of pathology. The purpose of this study was to develop an algorithm for the detection of muscularis propria invasion in urothelial carcinoma. Methods: The Training cohort consisted of 925 images from 50 specimens of urothelial carcinoma. Ninety-seven images from 10 new specimens were used as a validation cohort. Clinical validation used 127 whole specimens with a total of 617 slides. The algorithm determined areas where tumor and muscularis propria events were in nearest proximity, and presented these areas to the pathologist. Results: Analytical evaluation showed a sensitivity of 72% for muscularis propria and 65% for tumor, and a specificity of 46% and 77% for muscularis propria and tumor detection, respectively. The incorporation of the spatial proximity factor between muscularis propria and tumor in the clinical validation significantly improved the detection of muscularis propria invasion, as the algorithm managed to identify all except for one case with muscle invasive bladder cancer in the clinical validation cohort. The case missed by the algorithm was nested urothelial carcinoma, a rare subtype with unusual morphologic features. The pathologist managed to identify muscle invasion based on the images provided by the algorithm in a short time, with an average of approximately 5 s. Conclusion: The algorithm we developed may greatly aid in accurate identification of muscularis propria invasion by imitating the thought process of the pathologist.
This prospective, single-center, cross-sectional case control study will include a total of 68 women with pSS who presented to the rheumatology outpatient clinic of a tertiary care hospital and 135 healthy females who presented to the gynecology outpatient clinic for reasons other than sexual dysfunction and had similar age and menopausal status to the pSS group. The diagnosis of pSS was made according to the American-European Consensus Group criteria. Age, gravity, parity, body mass index (BMI), education status, smoking status, menarche age, and menopausal status and duration will be recorded for all participants. Disease duration, serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), anti-nuclear antibody (ANA) positivity, extractable nuclear antigen antibodies panel, extraglandular involvement and salivary gland pathologies were recorded. Disease-related variables (activity and function data, etc.), European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index (ESSPRI), EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), Clinical Disease Activity Index (CDAI), Disease Activity Score 28 (DAS28), Health Assessment Questionnaire (HAQ), Visual Analog Scale-Pain (VAS-Pain) and fatigue scores and medicines used for pSS will be evaluated and recorded only in the pSS group. A gynecological examination will be performed in the lithotomy position in all participants in both groups by the same gynecologist with at least 15 years of professional experience. In order to determine vaginal atrophy, shrinkage and thinning of the mucosa, loss of rugae in the vagina and introitus stenosis are taken into consideration. The reduction of subcutaneous fat in the labia majora is evaluated as labial atrophy, and contraction in size and even retraction of the clitoral prepuce is interpreted as clitoral atrophy. Pain sensation on speculum examination will be assessed by VAS (rated from 0 to 10). Vaginal culture and cervico-vaginal smear will be analyzed, and the findings will be recorded.

Women aged over 20 and under 70 years will be included in the study. Pregnant patients and those with known hepatic, renal, interstitial lung, gynecological oncological diseases, psychiatric disorders, and communication impairment will be excluded from the study. The Female Sexual Function Index (FSFI), Health Status Questionnaire \[Short Form (SF)-36\], and Hospital Depression and Anxiety Scale (HADS) will be administered to the women in both groups, and their scores were recorded. The data obtained from the study and control groups will be compared. The patients in the pSS group and healthy controls will be further divided into two subgroups according to their menopause status, and statistical comparisons will also be undertaken between these subgroups. A multivariate linear regression analysis will be performed, and the correlation of sexual function with other parameters is examined.
Many aspects of breast cancer metastasis remain poorly understood, despite its clinical importance. In this issue of the JCI, Winkler et al. have applied an elegant patient-derived xenograft (PDX) model to map the transcriptomes of single cells in matched primary tumors and lung metastases across 13 breast cancer PDX models. They identified distinct transcriptional changes associated with metastatic evolution in lowly and highly metastatic primary tumors. Furthermore, by classifying the "epithelial-mesenchymal plasticity" (EMP) state of single cells, they revealed that considerable EMP heterogeneity exists among primary and metastatic human breast cancer cells. However, the EMP profile of a tumor does not change substantially upon metastasis. These findings give an unprecedentedly detailed view into the transcriptional heterogeneity and evolution of metastatic human breast cancer.
Clinical Presentation

Acute overdosage with tramadol hydrochloride tablets can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, QT prolongation, hypotension, partial or complete airway obstruction, atypical snoring, seizures, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations.

Deaths due to overdose have been reported with abuse and misuse of tramadol [ see Warnings and Precautions (5.1); Drug Abuse and Dependence (9.2)]. Review of case reports has indicated that the risk of fatal overdose is further increased when tramadol is abused concurrently with alcohol or other CNS depressants, including other opioids. 

Treatment of Overdose

In case of overdose, priorities are the re-establishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or serious arrhythmias will require advanced life-supporting measures.

Opioid antagonists, such as naloxone, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to opioid overdose, administer an opioid antagonist.

While naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, the risk of seizures is also increased with naloxone administration. In animals, convulsions following the administration of toxic doses of tramadol hydrochloride tablets could be suppressed with barbiturates or benzodiazepines but were increased with naloxone. Naloxone administration did not change the lethality of an overdose in mice. Hemodialysis is not expected to be helpful in an overdose because it removes less than 7% of the administered dose in a 4-hour dialysis period.

Because the duration of opioid reversal is expected to be less than the duration of action of tramadol in tramadol hydrochloride tablets, carefully monitor the patient until spontaneous respiration is reliably re-established. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product's prescribing information.

In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist.
TIF1β/KAP1/TRIM28, a chromatin modulator, both represses and activates the transcription of genes in normal and malignant cells. Analyses of datasets on leukemia patients revealed that the expression level of TIF1β was increased in patients with chronic myeloid leukemia at the blast crisis and acute myeloid leukemia. We generated a BCR::ABL1 conditional knock-in (KI) mouse model, which developed aggressive myeloid leukemia, and demonstrated that the deletion of the Tif1β gene inhibited the progression of myeloid leukemia and showed longer survival than that in BCR::ABL1 KI mice, suggesting that Tif1β drove the progression of BCR::ABL1-induced leukemia. In addition, the deletion of Tif1β sensitized BCR::ABL1 KI leukemic cells to dasatinib. The deletion of Tif1β decreased the expression levels of TIF1β-target genes and chromatin accessibility peaks enriched with the Fosl1-binding motif in BCR::ABL1 KI stem cells. TIF1β directly bound to the promoters of proliferation genes, such as FOSL1, in human BCR::ABL1 cells, in which TIF1β and FOSL1 bound to adjacent regions of chromatin. Since the expression of Fosl1 was critical for the enhanced growth of BCR::ABL1 KI cells, Tif1β and Fosl1 interacted to activate the leukemic transcriptional program in and cellular function of BCR::ABL1 KI stem cells and drove the progression of myeloid leukemia.